These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 34771008)

  • 21. Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative.
    Coiro S; Girerd N; Rossignol P; Bauersachs J; Pitt B; Fay R; Ambrosio G; Solomon SD; Dickstein K; Zannad F
    Clin Res Cardiol; 2017 Sep; 106(9):722-733. PubMed ID: 28455597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin Receptor-Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials.
    Ravani LV; Gewehr DM; Calomeni P; Gauza MM; Pereira J; Cardoso R; Ribeiro HB; Bocchi E
    Am J Cardiol; 2023 Oct; 205():259-268. PubMed ID: 37619492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-Myocardial Infarction Heart Failure.
    Bahit MC; Kochar A; Granger CB
    JACC Heart Fail; 2018 Mar; 6(3):179-186. PubMed ID: 29496021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of retinal atherosclerosis assessed using Keith-Wagener-Barker system with incident heart failure and other atherosclerotic cardiovascular disease: Analysis of 319,501 individuals from the general population.
    Matsuoka S; Kaneko H; Okada A; Itoh H; Suzuki Y; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Nakamura S; Node K; Yasunaga H; Komuro I
    Atherosclerosis; 2022 May; 348():68-74. PubMed ID: 35292151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study.
    Andersson C; Mérie C; Jørgensen M; Gislason GH; Torp-Pedersen C; Overgaard C; Køber L; Jensen PF; Hlatky MA
    JAMA Intern Med; 2014 Mar; 174(3):336-44. PubMed ID: 24247428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intervention of Compound Xueshuantong Capsule on the incidence of heart failure in patients with acute myocardial infarction after PCI based on the combination of disease and syndrome: A multi-center, randomized, double-blind, controlled trial.
    Yang XD; Shi JX; Liao WC; Cui JY; Jin Z; Liu DL; Chen XL; Li R; Wu H; Luo C; Chu Q; Li R; Wu W; Qing L
    Medicine (Baltimore); 2022 Dec; 101(50):e32311. PubMed ID: 36550849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure.
    Jin H; Wyss JM; Yang R; Schwall R
    Curr Pharm Des; 2004; 10(20):2525-33. PubMed ID: 15320761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases.
    Dutka M; Bobiński R; Wojakowski W; Francuz T; Pająk C; Zimmer K
    Heart Fail Rev; 2022 Jul; 27(4):1395-1411. PubMed ID: 34313900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of acetylcholinesterase inhibitors on the heart in acute myocardial infarction and heart failure: From cells to patient reports.
    Khuanjing T; Palee S; Chattipakorn SC; Chattipakorn N
    Acta Physiol (Oxf); 2020 Feb; 228(2):e13396. PubMed ID: 31595611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives.
    Ferreira JP; Girerd N; Pellicori P; Duarte K; Girerd S; Pfeffer MA; McMurray JJ; Pitt B; Dickstein K; Jacobs L; Staessen JA; Butler J; Latini R; Masson S; Mebazaa A; Rocca HP; Delles C; Heymans S; Sattar N; Jukema JW; Cleland JG; Zannad F; Rossignol P;
    BMC Med; 2016 Nov; 14(1):181. PubMed ID: 27829460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New applications of erythropoietin in cardiovascular disease: from haematopoiesis to cardiac protection].
    van der Meer P; van Veldhuisen DJ
    Ned Tijdschr Geneeskd; 2008 Apr; 152(16):923-7. PubMed ID: 18561787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review.
    Harrington J; Petrie MC; Anker SD; Bhatt DL; Jones WS; Udell JA; Hernandez AF; Butler J
    JAMA Cardiol; 2022 Oct; 7(10):1067-1075. PubMed ID: 36044233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineered resveratrol-loaded fibrous scaffolds promotes functional cardiac repair and regeneration through Thioredoxin-1 mediated VEGF pathway.
    Campbell JD; Lakshmanan R; Selvaraju V; Accorsi D; McFadden DW; Maulik N; Thirunavukkarasu M
    Int J Pharm; 2021 Mar; 597():120236. PubMed ID: 33539996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic potential of resveratrol in heart failure.
    Sung MM; Dyck JR
    Ann N Y Acad Sci; 2015 Aug; 1348(1):32-45. PubMed ID: 26205211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.
    Spieker LE; Noll G; Lüscher TF
    Am J Cardiovasc Drugs; 2001; 1(4):293-303. PubMed ID: 14728028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure].
    Tereshchenko SN; Zhirov IV; Osmolovskaia IuF
    Ter Arkh; 2013; 85(12):137-43. PubMed ID: 24640683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway.
    Kanamori H; Takemura G; Goto K; Tsujimoto A; Ogino A; Takeyama T; Kawaguchi T; Watanabe T; Morishita K; Kawasaki M; Mikami A; Fujiwara T; Fujiwara H; Seishima M; Minatoguchi S
    Am J Pathol; 2013 Mar; 182(3):701-13. PubMed ID: 23274061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research.
    Li JZ; Li YR
    Cardiology; 2023; 148(4):374-384. PubMed ID: 37307806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.